The devices described herein are constructed in wire form where the wires diverge from a main bundle to form a variety of shapes that form a composite device. The benefit of such a diverging wire construction is that the composite complex device can be of a “joint-less” construction. Such devices have applicability in through-out the body, including clearing of blockages within body lumens, such as the vasculature, by addressing the frictional resistance on the obstruction prior to attempting to translate and/or mobilize the obstruction within the body lumen.
Many medical device applications require advancement of device in a reduced profile to a remote site within the body, where on reaching a target site, the device assumes or is deployed into a relatively larger profile. Applications in the cerebral vasculature are one such example of medical procedures where a catheter advances from a remote part of the body (typically a leg) through the vasculature and into the cerebral region of the vasculature to deploy a device. Accordingly, the deployed devices must be capable of achieving a larger profile while being able to fit within a small catheter or microcatheter. In addition, the degree to which a physician is limited in accessing remote regions of the cerebral vasculature is directly related to the limited ability of the device to constrain into a reduced profile for delivery.
Treatment of ischemic stroke is one such area where a need remains to deliver a device in a reduced profile and deploy the device to ultimately remove a blockage in an artery leading to the brain. Left untreated, the blockage causes a lack of supply of oxygen and nutrients to the brain tissue. The brain relies on its arteries to supply oxygenated blood from the heart and lungs. The blood returning from the brain carries carbon dioxide and cellular waste. Blockages that interfere with this supply eventually cause the brain tissue to stop functioning. If the disruption in supply occurs for a sufficient amount of time, the continued lack of nutrients and oxygen causes irreversible cell death (infarction). Accordingly, immediate medical treatment of an ischemic stroke is critical for the recovery of a patient.
Naturally, areas outside of ischemic stroke applications can also benefit from devices that can assume a profile for ultimate delivery to remote regions of the body.
Regardless of the area where the device is to be used, when fabricating such a device the joints between adjacent shapes or sections of the device often impede the ability of the device to assume a sufficiently reduced profile or interfere with the geometry/stiffness of the device causing problems when navigating the device through the body. Also, joints lead to potential failure locations, and may lead to fractured and embolized components within the body. Such joints may include welded, glued, or otherwise separately joined pieces into one or more points of connection.
Accordingly, a need remains for devices that can assume deployed configurations and are fabricated to eliminate or reduce the number of joints and/or connection points in the device. Doing so allows the device to have a compact and smooth configuration making it easier for delivery through a microcatheter, and leads to a safer device less prone to breaking or embolizing.
The examples discussed herein show the inventive device in a form that is suitable to retrieve obstructions or clots within the vasculature. The term obstructions may include blood clot, plaque, cholesterol, thrombus, naturally occurring foreign bodies (i.e., a part of the body that is lodged within the lumen), a non-naturally occurring foreign body (i.e., a portion of a medical device or other non-naturally occurring substance lodged within the lumen.) However, the devices are not limited to such applications and can apply to any number of medical applications where elimination or reduction of the number of connection points is desired.
In one variation of the devices described herein, the device comprises a main bundle or group of wires that diverge to form a device having various shapes but few or no connections points or joints (where fabrication of such a construction is referred to as “jointless”).
The term shape (or shaped section), when applied to the various shapes of the device, is intended to identify different parts of the device where the wires/fibers form different sections or portions of the device. Each such region or shape has a structure that serves a different function of the device. In one example of such a device, a first shape can be a connector portion and a second shape can be a basket or mesh shape. In this case, the first shape (the connector portion) has a different structure and serves a different function than the second shape (the basket or mesh shape). In another example, a first shape can be a connector portion, a second shape can be a traversing section, and the third shape can be a second connector shape. Again, each shape serves a different function (although in this example the first and third shapes may have similar structures). In most variations of the device, adjacent shapes will have different structures or will be separated by the wires that diverge/converge to form adjacent shapes (e.g., two adjacent shapes, each forming connector shapes but are separated by wires that traverse between the connector shapes). The different shapes may not necessarily be spaced axially along the device; instead, as shown below, two shapes may form a single connector portion (e.g., see
In one variation, the device is adapted for delivery through a catheter and includes a main bundle comprising a group of wires having a first end extending through the catheter and a second end, where the main bundle of wires diverge at the second end to form a first shaped section, the first shaped section further comprises an expanded profile and a reduced profile for delivery through the catheter, a plurality of individual subsets of wires each diverging from the first shaped section to form a second shaped section, and where the individual subsets of wires converge to form a third shaped section, where the third shaped section comprises an expanded profile and a reduced profile for delivery through the catheter, and where the convergence and divergence of wires occurs without junctions between wires.
The term diverge includes uncoupling or separating of joined wires. In addition, a group of wires that form a first shape may all diverge to form a new composite shape. For example, a bundle of wires may form a loop shape and ultimately bend to extend in a direction substantially normal to the loop shape. In such a case, the wires can be considered to diverge from the loop shape to form a second shape.
The devices of the present invention typically include a main bundle from which the wires extend. In most case, the main bundle extends for a length sufficient to withdraw the device from a body of a patient. Accordingly, in such cases, the main bundle shall extend through the length of a catheter. In alternate constructions, the main bundle may be affixed to a single wire or member. In such cases, the single wire or member is used to manipulate the device, which allows shortening of the length of the main bundle.
Devices of the present invention can incorporate any number of wires of different characteristics including, but not limited to, materials, shapes, sizes and/or diameters. Clearly, the number of permutations of device configurations is significant. Providing devices with such a composite construction allows for the manipulation of the device's properties to suite the intended application.
In an additional variation, the devices can also include a basket or mesh shape structure that assists in the removal of obstructions from the body. In some cases, these basket structures are used as a capturing section. Although any number of shapes is contemplated, a few examples of such shapes include a basket, a filter, a bag, a coil, a helical wire structure, a mesh, a single wound wire, and a plurality of crossing wires.
In some cases where the device is intended to remove obstructions from the vasculature, the device and catheter may be constructed to permit relative rotation of the ends of the device such that upon rotation a portion of the device converts to a high friction surface to aid in removing the obstruction.
As noted herein, the joint-less construction improves the flexibility and strength of the device by eliminating joints, connection points, or other attachment points. In addition, the joint-less construction improves the ability of the device to be delivered through a small microcatheter. As a result, the device and microcatheter are able to access remote regions of the vasculature.
The devices may be fabricated to be self-expanding upon deployment from a catheter. Alternatively, the devices can be constructed from shape-memory alloys such that they automatically deploy upon reaching a pre-determined transition temperature.
When used in the vasculature to retrieve obstructions, the devices may include a low friction mode (such as a set of parallel wires, or wires extending axially along the lumen or vessel) that converts to an increased friction mode (such as a compressed set of wires acting on the obstruction or a twisted set of wires acting on the obstruction). The increase in friction is an increase in the friction between the obstruction and the device (as opposed to the vessel wall. In some cases, the low friction mode is a low surface area mode and the high friction mode is a high surface area mode. When configured in the low friction mode, the device is better suited to engage the obstruction without the undesirable effect of prematurely mobilizing the obstruction or compacting the obstruction (e.g., when wires are slid across the obstruction in a transverse motion). Upon engaging the obstruction, the device will conform to a high friction mode with respect to the obstruction (in some cases the device will have an increased surface area mode). This high friction mode permits the device to better grip the obstruction for ultimate removal of the obstruction.
The operation of the devices and method described herein secure the obstruction, overcome the elastic forces of the obstruction, and then remove the obstruction from the anatomy without losing or fractionating the obstruction. In one variation of the invention, this is accomplished by the obstruction removal device interacting with the obstruction in the following manner: (1) a portion of the wires are delivered distal to the obstruction by passing either through the obstruction or between the obstruction and the vascular wall; (2) the traversing wires are pulled proximally to engage a basket shaped section of the device around the obstruction, the basket shaped section engages the obstruction without causing significant mobilization of the obstruction; (3) the device is pulled further proximally and the surrounding portion now mobilizes the obstruction.
As shown below, variations of the devices have a configuration that provides a path for a portion of the device to surround the obstruction. The paths are made using sets or subsets of wires that allow for low frictional translation of the device over the obstruction without causing axial translation of the obstruction. This mechanism is described in more detail below.
Once in the proper position, a portion of the device increases the frictional contact with the obstruction to disperse the pulling force more evenly across the obstruction. The increase points of contact allow for removal of the obstruction through tortuous anatomy while ensuring that the obstruction will not escape the encapsulation.
It should be noted that reference to surrounding, capturing or securing the obstruction includes partially and/or fully surrounding, engulfing, encapsulating, and/or securing the obstruction. In any case, a portion of the device engages the obstruction prior to translation of the obstruction within the lumen. As noted herein, a portion of the device may convert into a surrounding section (e.g., when wires reorient to increase the friction acting on the obstruction). Accordingly, these wires convert into a surrounding section.
It should be noted that in some variations of the invention, all or some of the device can be designed to increase their ability to adhere to the obstruction. For example, the wires may be coupled to an energy source (e.g., RF, ultrasonic, or thermal energy) to “weld” to the obstruction. Application of energy to the device can allow the surrounding portion to deform into the obstruction and “embed” within the obstruction. Alternatively, the device can impart a positive charge to the obstruction to partially liquefy the obstruction sufficiently to allow for easier removal. In another variation, a negative charge could be applied to further build thrombus and nest the device for better pulling force. The wires can be made stickier by use of a hydrophilic substance(s), or by chemicals that would generate a chemical bond to the surface of the obstruction. Alternatively, the filaments may reduce the temperature of the obstruction to congeal or adhere to the obstruction.
Additional devices and methods for treating ischemic stroke are discussed in commonly assigned U.S. patent application Ser. No. 11/671,450 filed Feb. 5, 2007; Ser. No. 11/684,521 filed Mar. 9, 2007; Ser. No. 11/684,535 filed Mar. 9, 2007; Ser. No. 11/684,541 filed Mar. 9, 2007; Ser. No. 11/684,546 filed Mar. 9, 2007; and Ser. No. 11/684,982 filed Mar. 12, 2007; the entirety of each of which is incorporated by reference. The principles of the invention as discussed herein may be applied to the above referenced cases to produce devices useful in treating ischemic stroke. In other words, the wire-shaped construction of devices according to present invention may assume the shapes disclosed in the above-referenced cases.
Each of the following figures diagrammatically illustrates aspects of the invention. Variation of the invention from the aspects shown in the figures is contemplated.
It is understood that the examples below discuss uses in the cerebral vasculature (namely the arteries). However, unless specifically noted, variations of the device and method are not limited to use in the cerebral vasculature. Instead, the invention may have applicability in various parts of the body. Moreover, the invention may be used in various procedures where the benefits of the method and/or device are desired.
It is noted that any number of catheters or microcatheters maybe used to locate the catheter/microcatheter 12 carrying the obstruction removal device (not illustrated) at the desired target site. Such techniques are well understood standard interventional catheterization techniques. Furthermore, the catheter 12 may be coupled to auxiliary or support components 14, 16 (e.g., energy controllers, power supplies, actuators for movement of the device(s), vacuum sources, inflation sources, sources for therapeutic substances, pressure monitoring, flow monitoring, various bio-chemical sensors, bio-chemical substance, etc.) Again, such components are within the scope of the system 10 described herein.
In addition, devices of the present invention may be packaged in kits including the components discussed above along with guiding catheters, various devices that assist in the stabilization or removal of the obstruction (e.g., proximal-assist devices that holds the proximal end of the obstruction in place preventing it from straying during removal or assisting in the removal of the obstruction), balloon-tipped guide catheters, dilators, etc.
Next, the wires 204 forming the first shape 206 diverge in groups or subsets of wires 212, 214, 216, 218, to form a second shaped section 220. Ultimately, the subsets of wires 212, 214, 216, 218 converge to form a third shaped section 224. The ends of the wires 204 may terminate in the final shape of the device. In other variations, the device is constructed such that the shapes formed by the divergence and convergence of the wires are formed by the center of the individual wires where all the ends of the wires are located in the main bundle 202. In such a configuration, the device will not contain any terminating ends. In such a case, the wires forming the shapes are continuous and the device is completely joint or connection free.
In the illustrated variation, the first shaped section and third shaped section 206, 224 form loop shapes while the second shaped section forms a series of traversing elements that extend between the loops. When formed into traversing elements, the wires extend substantially parallel to one another and normal to the shaped sections so that they can span between the first and third shaped sections.
As noted below, any number of shapes may be formed with this joint-less construction. In addition, the devices described herein may have any number of shaped sections. For example, in the illustrated variation, the first and second 206, 224 shaped sections form two loop type structures. However, the device may be constructed such that the wires diverge to form any number of looped shaped structures.
In any case, the individual wires 204 form a composite device 200 having individual sections that can serve various functions upon deployment of the device 200. The divergence and convergence of the wires minimizes the numbers of joints or connections that would otherwise be required to form the composite shape. Such a configuration produces a smooth geometry given that the wires forming the device 200 are continuous.
It is noted that any number of shapes, configurations, as well as any number of joined wires may be contemplated to form devices under the present disclosure. However, variations of the invention include selecting a number of wires 204 to produce specific structural properties to the device. For example, if it is desired that each subset 212, 214, 216, 218, have at least two wires, then naturally the first section, third section, and main bundle 202 must have at least two wires. However, in some cases, it may be desired that these sections have additional wires to impart the required characteristics. For example, in the illustrated variation, the main bundle may comprise any number of wires that do not diverge to form subsequent shapes in the device. In other words, not all of the wires forming a section are required to diverge to form an adjacent section. Instead, these non-diverging wires may simply “loop” back away from the device. In an additional variation, one or more wires may diverge to form a first shape and part of a second shape. Then the wires can loop back to converge again with the main bundle.
Of course, the opposite construction is also within the scope of this disclosure. Namely, that each wire from the main bundle diverges to form an adjacent section or shape.
As noted above, this variation of the device 200 include a plurality of subsets 212, 214, 216, 218 that traverse between the first and third shaped sections 206, 224. As shown in
Spacing the subsets that traverse across the obstruction can occur via a number of modes such as tensioning, expanding, spreading separating and/or withdrawing the wires. Regardless of the mode used, the subsets are intended to be positioned at or near a surface of the obstruction so that they can reduce the effects of any friction between the obstruction and the lumen or vessel wall.
Although the variation shows only four individual subsets of wires traversing across between the first and third shaped sections 206 and 224 any number subsets may be used so long as the rotation converts the wires into a relatively increased friction mode as compared to the low friction mode (when the subsets are in a parallel configuration). The low friction mode is represented by
In contrast, the device 200 may be configured to transform as shown in
The rotation of the ends of the device 206, 224 can be performed in any number of ways as known to those skilled in the art. In either case, the obstruction 2 becomes ensnared (and/or encapsulated) and can be removed from the body.
Next, as shown in
As shown, rotation of the shaped section 206 forms a twist point 116 proximal to the obstruction 2. In some cases, the subsets of wires 212, 214, 216, 218 can experience some twisting and may not remain parallel. The rotation of the shaped section 206 as well as the twist point 116 causes the subsets of wires 212, 214, 216, 218 to exert a compressive force on the obstruction 2 without crossing one another over the length of the obstruction. Accordingly, while the surface area in contact between the subsets of wires 212, 214, 216, 218 and obstruction 2 remains relatively the same, the compressive action of the subsets of wires onto the obstruction converts the device 200 to a high friction mode on the obstruction.
Next, the wires converge in the region marked as 234. It is noted that if the device is constructed on a planar fixture, the wires (once oriented) will be wrapped around a cylindrical structure and heat set to impart the shapes shown above. Accordingly, the regions marked by 232 and 234 assume partial loop shapes as the planar wire assembly is wrapped around the cylindrical fixture. In alternate variations, the wires may be oriented on a cylindrical fixture and heat set into a final shape. Doing so obviously eliminates the need to wrap the planar wire assembly about a cylindrical structure.
As shown, once the wires form the region marked as 234, they diverge once again to form a basket shaped section or filter 226 as discussed above. Accordingly, upon wrapping the device wires, the region marked as 234 assumes a loop shaped section. The wires forming the basket shaped section or filter 226 can either terminate at the end of the basket or filter 226. Alternatively, the wires can be looped around such that they eventually extend back through the main bundle 202 or loop back and terminate in any portion of the device.
The above described wire form construction allows for a number of configurations depending on the particular application. For example, the individual wires 204 may themselves comprise a bundle of smaller wires or filaments. In addition, the wires can be selected from materials such as stainless steel, titanium, platinum, gold, iridium, tantalum, nitinol, and/or polymeric strands. In addition, the wires used in a device may comprise a heterogeneous structure by using combinations of wires of different materials to produce a device having the particular desired properties. For example, one or more wires in the device may comprise a shape memory or superelastic alloy to impart predetermined shapes or resiliency to the device. In some variations, the mechanical properties of select wires can be altered. In such a case, the select wires can be treated to alter properties including: brittleness, ductility, elasticity, hardness, malleability, plasticity, strength, and toughness.
In addition, the device may include a number of radiopaque wires, such as gold and platinum for improved visibility under fluoroscopic imaging. In other words, any combination of materials may be incorporated into the device. In addition to the materials, the size of the wires may vary as needed. For example, the diameters of the wires may be the same or may vary as needed.
In addition, the individual wires may have cross-sectional shapes ranging from circular, oval, d-shaped, rectangular shape, etc. Moreover, the device is not limited to having wires having the same cross-sectional shape. Instead, the device can have wires having different cross-sectional shapes. To illustrate one such example, a device can have 8-12 wires made of 0.003″ round superelastic material (e.g., nitinol). The device may additionally have 2-4 wires made from 0.002″ platinum for fluoroscopy. Of the 8-12 nitinol wires, 1-4 of these wires can be made of a larger diameter or different cross-section to increase the overall strength of the device. Finally, a couple of polymer fibers can be added where the fibers have a desired surface property for clot adherence, etc. Such a combination of wires provides a composite device with properties not conventionally possible in view of other formation means (such as laser cutting or etching the shape from a tube or joining materials with welds, etc.). Clearly, any number of permutations is possible given the principles of the invention.
In another example, the device may be fabricated from wires formed from a polymeric material or composite blend of polymeric materials. The polymeric composite can be selected such that it is very floppy until it is exposed to either the body fluids and or some other delivered activator that causes the polymer to further polymerize or stiffen for strength. Various coatings could protect the polymer from further polymerizing before the device is properly placed. The coatings could provide a specific duration for placement (e.g., 5 minutes) after which the covering degrades or is activated with an agent (that doesn't affect the surrounding tissues) allowing the device to increase in stiffness so that it doesn't stretch as the thrombus is pulled out. For example, shape memory polymers would allow the device to increase in stiffness.
As discussed herein, the shaped section connectors may be other structures than loops. Moreover, variations of the invention include connectors that may be drawn down to a smaller size to facilitate removal from the body after securing the obstruction. This may be accomplished by torquing the device or part thereof, by re-sheathing part or all of the device or by any mechanical means designed into the features of the device itself. Any of these actions, or combination thereof, may also serve to compress or decrease the diameter of the obstruction itself to facilitate removal from the body.
As with the above examples, the illustrated variation shown above, the shaped portions are formed in a loop or partial loop shape. However, as described herein, the connectors may also comprise various alternate shapes (e.g., a circle, an arcuate shape, a partial circular shape, a loop, an oval, a square, a rectangle, a polygon, an overlapping loop, a pair of semi-circles, a flower shape, and a
The exemplary shapes discussed above permit the shaped section to adjust in diameter in response to placement in varying diameters of body lumens. It is noted that a device may have different shaped sections on different ends of the device.
While many different shapes are contemplated to be within the scope of this disclosure, the shapes will depend upon the ultimate application of the device. As noted herein, the illustrated examples have particular applicability in retrieving obstructions from the vasculature. Accordingly, for these applications the shaped sections should form a shape so that they can expand against a vessel wall without causing trauma to the vessel. For example, upon release from the catheter, the shaped section can assume their resting shape and expand within the vessel. The resting shape can be constructed to have a size slightly greater than that of the vessel. Sizing the device relative to the target vessel may assist in placing the parts of the device against a vessel.
In an additional aspect, the shaped sections may be designed to have an unconstrained shape that is larger than the intended target vessel or simply different than a cross sectional profile of the intended vessel (i.e., not circular or tubular, but e.g., linear or other different shape). In such an example, as the shaped section is released from the delivery catheter, the shape section attempts to return to the unconstrained shape. In those variations where the unconstrained shape is different from the circular profile of the vessel, the leading wire assumes a shape that accommodates the vessel but is more rigid and stable since its unconstrained shape is entirely different from that of the vessel. In other words, the shaped section continually exerts an outward force on the vessel.
In yet another aspect, the shaped sections shown herein may not necessarily lie in the same plane. Instead, they can be axially spaced by an offset. One benefit of constructing the device to have non-planar shaped section is that the configuration might allow for delivery of the device delivered via a smaller microcatheter because the shaped sections do not interfere with one another when collapsed to fit within the microcatheter.
Another aspect applicable to all variations of the devices is to configure the devices (whether the traversing filament or the surrounding portion) for better adherence to the obstruction. One such mode includes the use of coatings that bond to certain clots (or other materials causing the obstruction.) For example, the wires may be coated with a hydrogel or adhesive that bonds to a thrombus. Accordingly, as the device secures about a clot, the combination of the additive and the mechanical structure of the device may improve the effectiveness of the device in removing the obstruction.
Such improvements may also be mechanical or structural. For example, as shown in
In addition to additives, the device can be coupled to an RF or other power source (such as 14 or 16 in
The methods described herein may also include treating the obstruction prior to attempting to remove the obstruction. Such a treatment can include applying a chemical or pharmaceutical agent with the goal of making the occlusion shrink or to make it more rigid for easier removal. Such agents include, but are not limited to chemotherapy drugs, or solutions, a mild formalin, or aldehyde solution.
Although not illustrated, the devices and methods described herein may also be useful in removing obstructions lodged within bifurcations in the anatomy. Generally, bifurcations greatly increase the frictional forces on the obstructions since the obstruction tends to be lodged in both branching sections of the bifurcation. In such cases, the use of the presently described devices and methods may also include an additional “puller” device that advances beyond the portion of the obstruction partially located in the bifurcated vessel.
As for other details of the present invention, materials and manufacturing techniques may be employed as within the level of those with skill in the relevant art. The same may hold true with respect to method-based aspects of the invention in terms of additional acts that are commonly or logically employed. In addition, though the invention has been described in reference to several examples, optionally incorporating various features, the invention is not to be limited to that which is described or indicated as contemplated with respect to each variation of the invention.
As noted above, the shapes 206 may range from a circle, an arcuate shape, a partial circular shape, a loop, an oval, a square, a rectangle, a polygon, an overlapping loop, a pair of semi-circles, a flower shape, and a
Various changes may be made to the invention described and equivalents (whether recited herein or not included for the sake of some brevity) may be substituted without departing from the true spirit and scope of the invention. Also, any optional feature of the inventive variations may be set forth and claimed independently, or in combination with any one or more of the features described herein. Accordingly, the invention contemplates combinations of various aspects of the embodiments or combinations of the embodiments themselves, where possible. Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “and,” “said,” and “the” include plural references unless the context clearly dictates otherwise.
This application is a continuation of U.S. patent application Ser. No. 16/119,891, filed Aug. 31, 2018, which is a continuation of U.S. patent application Ser. No. 15/056,456, filed on Feb. 29, 2016, now U.S. Pat. No. 10,076,346, which is a continuation of U.S. patent application Ser. No. 13/946,901, filed on Jul. 19, 2013, now U.S. Pat. No. 9,271,747, which is a continuation of U.S. patent application Ser. No. 11/736,537, filed on Apr. 17, 2007, now U.S. Pat. No. 8,512,352, all of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
1054960 | Butner | Mar 1913 | A |
2918919 | Wallace | Dec 1959 | A |
2943626 | Enrico | Jul 1960 | A |
3108593 | Glassman | Oct 1963 | A |
3108594 | Glassman | Oct 1963 | A |
3996938 | Clark | Dec 1976 | A |
4347846 | Dormia | Sep 1982 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4612931 | Dormia | Sep 1986 | A |
4633871 | Shinozuka | Jan 1987 | A |
4699147 | Chilson et al. | Oct 1987 | A |
4790812 | Hawkins, Jr. et al. | Dec 1988 | A |
4807626 | Mcgirr | Feb 1989 | A |
4832055 | Palestrant | May 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4969891 | Gewertz | Nov 1990 | A |
5057114 | Wittich et al. | Oct 1991 | A |
5059178 | Ya | Oct 1991 | A |
5098441 | Wechler | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5147400 | Kaplan et al. | Sep 1992 | A |
5152777 | Goldberg et al. | Oct 1992 | A |
5190554 | Coddington, III et al. | Mar 1993 | A |
5192286 | Phan et al. | Mar 1993 | A |
5300086 | Gory et al. | Apr 1994 | A |
5330482 | Gibbs et al. | Jul 1994 | A |
5397320 | Essig et al. | Mar 1995 | A |
5443478 | Purdy | Aug 1995 | A |
5458375 | Anspach, Jr. et al. | Oct 1995 | A |
5496330 | Bates et al. | Mar 1996 | A |
5509900 | Kirkman | Apr 1996 | A |
5611803 | Heaven et al. | Mar 1997 | A |
5653684 | Laptewicz et al. | Aug 1997 | A |
5658296 | Bates et al. | Aug 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5733302 | Myler et al. | Mar 1998 | A |
5741325 | Chaikof et al. | Apr 1998 | A |
5792156 | Perouse | Aug 1998 | A |
5827324 | Cassell et al. | Oct 1998 | A |
5846251 | Hart | Dec 1998 | A |
5895398 | Wensel et al. | Apr 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5968090 | Ratcliff et al. | Oct 1999 | A |
5971938 | Hart et al. | Oct 1999 | A |
5972019 | Engelson et al. | Oct 1999 | A |
5989266 | Foster | Nov 1999 | A |
6001118 | Daniel et al. | Dec 1999 | A |
6033394 | Vidlund et al. | Mar 2000 | A |
6053932 | Daniel et al. | Apr 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates et al. | Aug 2000 | A |
6159220 | Gobron et al. | Dec 2000 | A |
6165200 | Tsugita et al. | Dec 2000 | A |
6168579 | Tsugita | Jan 2001 | B1 |
6168603 | Leslie et al. | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6190394 | Lind et al. | Feb 2001 | B1 |
6217609 | Haverkost | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6224612 | Bates et al. | May 2001 | B1 |
6245089 | Daniel et al. | Jun 2001 | B1 |
6248113 | Fina | Jun 2001 | B1 |
6264664 | Avellanet | Jul 2001 | B1 |
6299612 | Ouchi | Oct 2001 | B1 |
6302895 | Gobron et al. | Oct 2001 | B1 |
6309399 | Barbut et al. | Oct 2001 | B1 |
6325807 | Que | Dec 2001 | B1 |
6348056 | Bates et al. | Feb 2002 | B1 |
6350266 | White et al. | Feb 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6383195 | Richard | May 2002 | B1 |
6383196 | Leslie et al. | May 2002 | B1 |
6402761 | Mcalister | Jun 2002 | B2 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6416505 | Fleischman et al. | Jul 2002 | B1 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6436112 | Wensel et al. | Aug 2002 | B2 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6485497 | Wensel et al. | Nov 2002 | B2 |
6494884 | Gifford, III et al. | Dec 2002 | B2 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6514273 | Voss et al. | Feb 2003 | B1 |
6517550 | Konya et al. | Feb 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6537297 | Tsugita et al. | Mar 2003 | B2 |
6540657 | Cross, III et al. | Apr 2003 | B2 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6585753 | Eder et al. | Jul 2003 | B2 |
6592605 | Lenker et al. | Jul 2003 | B2 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6602265 | Dubrul et al. | Aug 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi et al. | Sep 2003 | B1 |
6620148 | Tsugita | Sep 2003 | B1 |
6620172 | Dretler et al. | Sep 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6636758 | Sanchez et al. | Oct 2003 | B2 |
6638245 | Miller et al. | Oct 2003 | B2 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6645199 | Jenkins et al. | Nov 2003 | B1 |
6652505 | Tsugita | Nov 2003 | B1 |
6652537 | Mercereau et al. | Nov 2003 | B2 |
6652548 | Evans et al. | Nov 2003 | B2 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6673042 | Samson et al. | Jan 2004 | B1 |
6673080 | Reynolds et al. | Jan 2004 | B2 |
6679893 | Tran | Jan 2004 | B1 |
6685738 | Chouinard et al. | Feb 2004 | B2 |
6692508 | Wensel et al. | Feb 2004 | B2 |
6692509 | Wensel et al. | Feb 2004 | B2 |
6695858 | Dubrul et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6709465 | Mitchell et al. | Mar 2004 | B2 |
6712835 | Mazzocchi et al. | Mar 2004 | B2 |
6730104 | Sepetka et al. | May 2004 | B1 |
6740096 | Teague et al. | May 2004 | B2 |
6745080 | Koblish | Jun 2004 | B2 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6749619 | Ouriel et al. | Jun 2004 | B2 |
6755813 | Ouriel et al. | Jun 2004 | B2 |
6800080 | Bates | Oct 2004 | B1 |
6824545 | Sepetka et al. | Nov 2004 | B2 |
6840950 | Stanford et al. | Jan 2005 | B2 |
6872211 | White et al. | Mar 2005 | B2 |
6872216 | Daniel et al. | Mar 2005 | B2 |
6890341 | Dieck et al. | May 2005 | B2 |
6893431 | Naimark et al. | May 2005 | B2 |
6905503 | Gifford, III et al. | Jun 2005 | B2 |
6913612 | Palmer et al. | Jul 2005 | B2 |
6936059 | Belef | Aug 2005 | B2 |
6939362 | Boyle et al. | Sep 2005 | B2 |
6945977 | Demarais et al. | Sep 2005 | B2 |
6953465 | Dieck et al. | Oct 2005 | B2 |
6964672 | Brady et al. | Nov 2005 | B2 |
7004955 | Shen et al. | Feb 2006 | B2 |
7004956 | Palmer et al. | Feb 2006 | B2 |
7037320 | Brady et al. | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7101380 | Khachin et al. | Sep 2006 | B2 |
7169165 | Belef et al. | Jan 2007 | B2 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7182771 | Houser et al. | Feb 2007 | B1 |
7220271 | Clubb et al. | May 2007 | B2 |
7235061 | Tsugita | Jun 2007 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7534252 | Sepetka et al. | May 2009 | B2 |
7591825 | Leslie et al. | Sep 2009 | B2 |
7691121 | Rosenbluth et al. | Apr 2010 | B2 |
7731722 | Lavelle et al. | Jun 2010 | B2 |
8105333 | Sepetka et al. | Jan 2012 | B2 |
8142445 | Teague | Mar 2012 | B2 |
8157811 | Shinozuka et al. | Apr 2012 | B2 |
8211115 | Cheng et al. | Jul 2012 | B2 |
8267940 | Sepetka et al. | Sep 2012 | B2 |
8512352 | Martin | Aug 2013 | B2 |
8535334 | Martin | Sep 2013 | B2 |
8545526 | Martin et al. | Oct 2013 | B2 |
8603014 | Alleman et al. | Dec 2013 | B2 |
8801748 | Martin | Aug 2014 | B2 |
8837800 | Bammer et al. | Sep 2014 | B1 |
9119656 | Bose et al. | Sep 2015 | B2 |
9126018 | Garrison | Sep 2015 | B1 |
9211132 | Bowman | Dec 2015 | B2 |
9241699 | Kume et al. | Jan 2016 | B1 |
9254371 | Martin et al. | Feb 2016 | B2 |
9265512 | Garrison et al. | Feb 2016 | B2 |
9271747 | Martin | Mar 2016 | B2 |
9271748 | Martin | Mar 2016 | B2 |
9308007 | Cully et al. | Apr 2016 | B2 |
9399118 | Kume et al. | Jul 2016 | B2 |
9445828 | Turjman et al. | Sep 2016 | B2 |
9445829 | Brady et al. | Sep 2016 | B2 |
9492637 | Garrison et al. | Nov 2016 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9561345 | Garrison et al. | Feb 2017 | B2 |
9579119 | Cully et al. | Feb 2017 | B2 |
9585741 | Ma | Mar 2017 | B2 |
9642635 | Vale et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9717514 | Martin et al. | Aug 2017 | B2 |
9737318 | Monstadt et al. | Aug 2017 | B2 |
9770251 | Bowman et al. | Sep 2017 | B2 |
9801643 | Hansen et al. | Oct 2017 | B2 |
9861783 | Garrison et al. | Jan 2018 | B2 |
9993257 | Losordo et al. | Jun 2018 | B2 |
10028782 | Orion | Jul 2018 | B2 |
10029008 | Creighton | Jul 2018 | B2 |
10039906 | Kume et al. | Aug 2018 | B2 |
10076346 | Martin | Sep 2018 | B2 |
10925625 | Martin | Feb 2021 | B2 |
20010031971 | Dretler et al. | Oct 2001 | A1 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010044634 | Don et al. | Nov 2001 | A1 |
20010051810 | Dubrul et al. | Dec 2001 | A1 |
20020002396 | Fulkerson | Jan 2002 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020026211 | Khosravi et al. | Feb 2002 | A1 |
20020058904 | Boock et al. | May 2002 | A1 |
20020062135 | Mazzocchi et al. | May 2002 | A1 |
20020072764 | Sepetka et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020123765 | Sepetka et al. | Sep 2002 | A1 |
20020151928 | Leslie et al. | Oct 2002 | A1 |
20020169474 | Kusleika et al. | Nov 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193825 | Mcguckin et al. | Dec 2002 | A1 |
20030004542 | Wensel et al. | Jan 2003 | A1 |
20030023265 | Forber | Jan 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin et al. | Mar 2003 | A1 |
20030060782 | Bose et al. | Mar 2003 | A1 |
20030093087 | Jones et al. | May 2003 | A1 |
20030139750 | Shinozuka et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030153935 | Mialhe | Aug 2003 | A1 |
20030191492 | Gellman et al. | Oct 2003 | A1 |
20030195556 | Stack et al. | Oct 2003 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20040079429 | Miller et al. | Apr 2004 | A1 |
20040116941 | Reynolds et al. | Jun 2004 | A1 |
20040122445 | Butler et al. | Jun 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138692 | Phung et al. | Jul 2004 | A1 |
20040153025 | Seifert et al. | Aug 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20040199201 | Kellett et al. | Oct 2004 | A1 |
20040199243 | Yodfat | Oct 2004 | A1 |
20040210116 | Nakao | Oct 2004 | A1 |
20040267301 | Boylan et al. | Dec 2004 | A1 |
20050004594 | Nool et al. | Jan 2005 | A1 |
20050033348 | Sepetka et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050043680 | Segal et al. | Feb 2005 | A1 |
20050043756 | Lavelle et al. | Feb 2005 | A1 |
20050049619 | Sepetka et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059995 | Sepetka et al. | Mar 2005 | A1 |
20050075648 | Komiya | Apr 2005 | A1 |
20050080356 | Dapolito et al. | Apr 2005 | A1 |
20050085826 | Nair et al. | Apr 2005 | A1 |
20050085847 | Galdonik et al. | Apr 2005 | A1 |
20050085849 | Sepetka et al. | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050090858 | Pavlovic | Apr 2005 | A1 |
20050096668 | Mcalister | May 2005 | A1 |
20050125024 | Sepetka et al. | Jun 2005 | A1 |
20050131450 | Nicholson et al. | Jun 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050203571 | Mazzocchi et al. | Sep 2005 | A1 |
20050209609 | Wallace | Sep 2005 | A1 |
20050216030 | Sepetka et al. | Sep 2005 | A1 |
20050216050 | Sepetka et al. | Sep 2005 | A1 |
20050234501 | Barone | Oct 2005 | A1 |
20050234505 | Diaz et al. | Oct 2005 | A1 |
20050251151 | Teague | Nov 2005 | A1 |
20050261706 | Cheng et al. | Nov 2005 | A1 |
20050267491 | Kellett et al. | Dec 2005 | A1 |
20050277978 | Greenhalgh | Dec 2005 | A1 |
20050283166 | Greenhalgh | Dec 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20060004404 | Khachin et al. | Jan 2006 | A1 |
20060009784 | Behl et al. | Jan 2006 | A1 |
20060047286 | West | Mar 2006 | A1 |
20060058836 | Bose et al. | Mar 2006 | A1 |
20060058837 | Bose et al. | Mar 2006 | A1 |
20060058838 | Bose et al. | Mar 2006 | A1 |
20060095070 | Gilson et al. | May 2006 | A1 |
20060129166 | Lavelle | Jun 2006 | A1 |
20060129180 | Tsugita et al. | Jun 2006 | A1 |
20060155305 | Freudenthal et al. | Jul 2006 | A1 |
20060190070 | Dieck et al. | Aug 2006 | A1 |
20060195137 | Sepetka et al. | Aug 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060253145 | Lucas | Nov 2006 | A1 |
20060276805 | Yu | Dec 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060293697 | Nakao et al. | Dec 2006 | A1 |
20070112374 | Paul et al. | May 2007 | A1 |
20070118165 | Demello et al. | May 2007 | A1 |
20070185500 | Martin et al. | Aug 2007 | A1 |
20070185501 | Martin et al. | Aug 2007 | A1 |
20070197103 | Martin et al. | Aug 2007 | A1 |
20070198029 | Martin et al. | Aug 2007 | A1 |
20070198030 | Martin et al. | Aug 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070225749 | Martin et al. | Sep 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20080109031 | Sepetka et al. | May 2008 | A1 |
20080183198 | Sepetka et al. | Jul 2008 | A1 |
20080188885 | Sepetka et al. | Aug 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20090069828 | Martin et al. | Mar 2009 | A1 |
20090192518 | Leanna et al. | Jul 2009 | A1 |
20090287291 | Becking et al. | Nov 2009 | A1 |
20090299393 | Martin et al. | Dec 2009 | A1 |
20100076452 | Sepetka et al. | Mar 2010 | A1 |
20100185210 | Hauser et al. | Jul 2010 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110288572 | Martin | Nov 2011 | A1 |
20120143230 | Sepetka et al. | Jun 2012 | A1 |
20120197285 | Martin et al. | Aug 2012 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20140005717 | Martin et al. | Jan 2014 | A1 |
20140031856 | Martin | Jan 2014 | A1 |
20140148841 | Martin | May 2014 | A1 |
20140276074 | Warner | Sep 2014 | A1 |
20140343595 | Monstadt et al. | Nov 2014 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160015935 | Chan et al. | Jan 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160151618 | Powers et al. | Jun 2016 | A1 |
20160157985 | Vo et al. | Jun 2016 | A1 |
20160174996 | Martin | Jun 2016 | A1 |
20160199620 | Pokorney et al. | Jul 2016 | A1 |
20160296690 | Kume et al. | Oct 2016 | A1 |
20160302808 | Loganathan et al. | Oct 2016 | A1 |
20160375180 | Anzai | Dec 2016 | A1 |
20170079766 | Wang et al. | Mar 2017 | A1 |
20170079767 | Leon-yip | Mar 2017 | A1 |
20170086862 | Vale et al. | Mar 2017 | A1 |
20170100143 | Grandfield | Apr 2017 | A1 |
20170105743 | Vale et al. | Apr 2017 | A1 |
20170164963 | Goyal | Jun 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170281909 | Northrop et al. | Oct 2017 | A1 |
20170290599 | Youn et al. | Oct 2017 | A1 |
20180049762 | Seip et al. | Feb 2018 | A1 |
20180084982 | Yamashita et al. | Mar 2018 | A1 |
20180116717 | Taff et al. | May 2018 | A1 |
20180132876 | Zaidat | May 2018 | A1 |
20180140314 | Goyal et al. | May 2018 | A1 |
20180140315 | Bowman et al. | May 2018 | A1 |
20180140354 | Lam et al. | May 2018 | A1 |
20180185614 | Garrison et al. | Jul 2018 | A1 |
20190015121 | Martin | Jan 2019 | A1 |
Number | Date | Country |
---|---|---|
3501707 | Jul 1986 | DE |
1312314 | May 2003 | EP |
2319575 | Nov 2013 | EP |
2002537943 | Nov 2002 | JP |
2008539958 | Nov 2008 | JP |
2014004219 | Jan 2014 | JP |
2018118132 | Aug 2018 | JP |
20180102877 | Sep 2018 | KR |
WO 9409845 | May 1994 | WO |
WO 9509586 | Apr 1995 | WO |
WO 9601591 | Jan 1996 | WO |
WO 9617634 | Jun 1996 | WO |
WO 9619941 | Jul 1996 | WO |
WO 9727808 | Aug 1997 | WO |
WO 9727893 | Aug 1997 | WO |
WO 9803120 | Jan 1998 | WO |
WO 0053120 | Sep 2000 | WO |
WO 0072909 | Dec 2000 | WO |
WO 0132254 | May 2001 | WO |
WO 0154622 | Aug 2001 | WO |
WO 0167967 | Sep 2001 | WO |
WO 0202162 | Jan 2002 | WO |
WO 0228291 | Apr 2002 | WO |
WO 03000334 | Jan 2003 | WO |
WO 03061730 | Jul 2003 | WO |
WO 03089039 | Oct 2003 | WO |
WO 2006031410 | Mar 2006 | WO |
WO 2006122076 | Nov 2006 | WO |
WO 2007092820 | Aug 2007 | WO |
WO 2008036156 | Mar 2008 | WO |
WO 2008131116 | Oct 2008 | WO |
WO 2009034456 | Mar 2009 | WO |
WO 2009086482 | Jul 2009 | WO |
WO 2011091383 | Jul 2011 | WO |
WO 2012009675 | Jan 2012 | WO |
WO 2012162437 | Nov 2012 | WO |
WO 2015141317 | Sep 2015 | WO |
WO 2017192999 | Nov 2017 | WO |
WO 2018019829 | Feb 2018 | WO |
WO 2018033401 | Feb 2018 | WO |
WO 2018046408 | Mar 2018 | WO |
WO 2018137029 | Aug 2018 | WO |
WO 2018137030 | Aug 2018 | WO |
WO 2018145212 | Aug 2018 | WO |
WO 2018156813 | Aug 2018 | WO |
WO 2018172891 | Sep 2018 | WO |
WO 2018187776 | Oct 2018 | WO |
Entry |
---|
Extended European Search Report dated Apr. 7, 2017; European Application No. 08807060.2; 9 pages. |
Number | Date | Country | |
---|---|---|---|
20210177443 A1 | Jun 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16119891 | Aug 2018 | US |
Child | 17249134 | US | |
Parent | 15056456 | Feb 2016 | US |
Child | 16119891 | US | |
Parent | 13946901 | Jul 2013 | US |
Child | 15056456 | US | |
Parent | 11736537 | Apr 2007 | US |
Child | 13946901 | US |